CircRNA-3302 promotes endothelial-to-mesenchymal transition via sponging miR-135b-5p to enhance KIT expression in Kawasaki disease.

Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
29 Jun 2022
Historique:
received: 04 04 2022
accepted: 16 06 2022
revised: 15 06 2022
entrez: 29 6 2022
pubmed: 30 6 2022
medline: 30 6 2022
Statut: epublish

Résumé

Endothelial-to-mesenchymal transition (EndMT) is implicated in myofibroblast-like cell-mediated damage to coronary artery wall of Kawasaki disease (KD) patients, which subsequently increases the risk of coronary artery aneurysm. Many circular RNAs (circRNAs) have been reported to be associated with cardiovascular diseases. However, the roles and underlying molecular mechanism of circRNAs in KD-associated EndMT remains indefinite. In this research, we screened out circRNA-3302 from human umbilical vein endothelial cells (HUVECs) treated by sera from healthy controls (HCs) or KD patients via circRNA sequencing (circRNA-seq). In addition, circRNA-3302 upregulation was verified in endothelial cells stimulated by KD serum and pathological KD mice modeled with Candida albicans cell wall extracts (CAWS). Moreover, in vitro experiments demonstrated that overexpression of circRNA-3302 could markedly induce EndMT, and silencing of circRNA-3302 significantly alleviated KD serum-mediated EndMT. To further explore the molecular mechanisms of circRNA-3302 inducing EndMT, RNA sequencing (RNA-seq), a dual-luciferase reporter system, nuclear and extra-nuclear RNA isolation, RT-qPCR and Western blot analyses and so on, were utilized. Our data demonstrated that circRNA-3302 contributed to the KD-associated EndMT via sponging miR-135b-5p to enhance KIT expression. Collectively, our results imply that circRNA-3302 plays an important role in KD-associated EndMT, providing new insights into minimizing the risks of developing coronary artery aneurysms.

Identifiants

DOI: 10.1038/s41420-022-01092-4 PMID: 35768408 PMC: PMC9243129
pubmed: 35768408
doi: 10.1038/s41420-022-01092-4
pii: 10.1038/s41420-022-01092-4
pmc: PMC9243129
doi:

Types de publication

Journal Article

Langues

eng

Pagination

299

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : No. 81970435
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : No. 82000469
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : No. 82100523
Organisme : Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation)
ID : LY19H030004

Informations de copyright

© 2022. The Author(s).

Références

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for Health Professionals From the American Heart Association. Circulation. 2017;135:e927–e99.
pubmed: 28356445 doi: 10.1161/CIR.0000000000000484
Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67:1738–49.
pubmed: 27056781 doi: 10.1016/j.jacc.2015.12.073
Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol. 2020;16:391–405.
pubmed: 32457494 pmcid: 7250272 doi: 10.1038/s41584-020-0426-0
Murphy DJ Jr., Huhta JC. Treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1987;316:881.
pubmed: 2434852 doi: 10.1056/NEJM198704023161415
Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153:117–21.
pubmed: 18571548 pmcid: 2526555 doi: 10.1016/j.jpeds.2007.12.021
He M, Chen Z, Martin M, Zhang J, Sangwung P, Woo B, et al. MiR-483 Targeting of CTGF suppresses endothelial-to-mesenchymal transition: therapeutic implications in kawasaki disease. Circulation Res. 2017;120:354–65.
pubmed: 27923814 doi: 10.1161/CIRCRESAHA.116.310233
Li Y, Lui KO, Zhou B. Reassessing endothelial-to-mesenchymal transition in cardiovascular diseases. Nat Rev Cardiol. 2018;15:445–56.
pubmed: 29748594 doi: 10.1038/s41569-018-0023-y
Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol. 2012;22:379–84.
pubmed: 22554794 pmcid: 3422405 doi: 10.1016/j.semcancer.2012.04.004
Kovacic JC, Dimmeler S, Harvey RP, Finkel T, Aikawa E, Krenning G, et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:190–209.
pubmed: 30654892 pmcid: 6865825 doi: 10.1016/j.jacc.2018.09.089
Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131:1006–18.
pubmed: 25593290 doi: 10.1161/CIRCULATIONAHA.114.008750
Arciniegas E, Frid MG, Douglas IS, Stenmark KR. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293:L1–8.
pubmed: 17384082 doi: 10.1152/ajplung.00378.2006
Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740–6.
pubmed: 14644200 doi: 10.1016/j.ceb.2003.10.006
Pérez L, Muñoz-Durango N, Riedel CA, Echeverría C, Kalergis AM, Cabello-Verrugio C, et al. Endothelial-to-mesenchymal transition: cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine growth factor Rev. 2017;33:41–54.
pubmed: 27692608 doi: 10.1016/j.cytogfr.2016.09.002
Shimizu C, Oharaseki T, Takahashi K, Kottek A, Franco A, Burns JC. The role of TGF-β and myofibroblasts in the arteritis of Kawasaki disease. Hum Pathol. 2013;44:189–98.
pubmed: 22955109 doi: 10.1016/j.humpath.2012.05.004
Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circulation Res. 2001;89:1111–21.
pubmed: 11739275 doi: 10.1161/hh2401.100844
Su H, Tao T, Yang Z, Kang X, Zhang X, Kang D, et al. Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Mol Cancer. 2019;18:27.
pubmed: 30782157 pmcid: 6379985 doi: 10.1186/s12943-019-0951-0
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.
pubmed: 23446346 doi: 10.1038/nature11993
Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15:409.
pubmed: 25070500 pmcid: 4165365 doi: 10.1186/s13059-014-0409-z
Rybak-Wolf A, Stottmeister C, Glažar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015;58:870–85.
pubmed: 25921068 doi: 10.1016/j.molcel.2015.03.027
Devaux Y, Creemers EE, Boon RA, Werfel S, Thum T, Engelhardt S, et al. Circular RNAs in heart failure. Eur J Heart Fail. 2017;19:701–9.
pubmed: 28345158 doi: 10.1002/ejhf.801
Fan X, Weng X, Zhao Y, Chen W, Gan T, Xu D. Circular RNAs in cardiovascular disease: an overview. BioMed Res Int. 2017;2017:5135781.
pubmed: 28210621 pmcid: 5292166 doi: 10.1155/2017/5135781
Li M, Ding W, Sun T, Tariq MA, Xu T, Li P, et al. Biogenesis of circular RNAs and their roles in cardiovascular development and pathology. FEBS J. 2018;285:220–32.
pubmed: 28783257 doi: 10.1111/febs.14191
Wang H, Yang J, Yang J, Fan Z, Yang C. Circular RNAs: novel rising stars in cardiovascular disease research. Int J Cardiol. 2016;202:726–7.
pubmed: 26461920 doi: 10.1016/j.ijcard.2015.10.051
Vausort M, Salgado-Somoza A, Zhang L, Leszek P, Scholz M, Teren A, et al. Myocardial infarction-associated circular rna predicting left ventricular dysfunction. J Am Coll Cardiol. 2016;68:1247–8.
pubmed: 27609688 doi: 10.1016/j.jacc.2016.06.040
Tang CM, Zhang M, Huang L, Hu ZQ, Zhu JN, Xiao Z, et al. CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Sci Rep. 2017;7:40342.
pubmed: 28079129 pmcid: 5228128 doi: 10.1038/srep40342
Zhou B, Yu JW. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res Commun. 2017;487:769–75.
pubmed: 28412345 doi: 10.1016/j.bbrc.2017.04.044
Zheng C, Niu H, Li M, Zhang H, Yang Z, Tian L, et al. Cyclic RNA hsa‑circ‑000595 regulates apoptosis of aortic smooth muscle cells. Mol Med Rep. 2015;12:6656–62.
pubmed: 26324352 pmcid: 4626120 doi: 10.3892/mmr.2015.4264
Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Péchoux C, Bogaard HJ, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131:1006–18.
pubmed: 25593290 doi: 10.1161/CIRCULATIONAHA.114.008750
Yoshimatsu Y, Wakabayashi I, Kimuro S, Takahashi N, Takahashi K, Kobayashi M, et al. TNF-α enhances TGF-β-induced endothelial-to-mesenchymal transition via TGF-β signal augmentation. Cancer Sci. 2020;111:2385–99.
pubmed: 32385953 pmcid: 7385392 doi: 10.1111/cas.14455
Li Q, Lai Q, He C, Fang Y, Yan Q, Zhang Y, et al. RUNX1 promotes tumour metastasis by activating the Wnt/β-catenin signalling pathway and EMT in colorectal cancer. J Exp Clin Cancer Res. 2019;38:334.
pubmed: 31370857 pmcid: 6670220 doi: 10.1186/s13046-019-1330-9
Monteiro JP, Rodor J, Caudrillier A, Scanlon JP, Spiroski AM, Dudnakova T, et al. MIR503HG loss promotes endothelial-to-mesenchymal transition in vascular disease. Circulation Res. 2021;128:1173–90.
pubmed: 33703914 doi: 10.1161/CIRCRESAHA.120.318124
Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell 2019;177:865–80.e21.
pubmed: 31031002 doi: 10.1016/j.cell.2019.03.046
Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in cancer. Cell 2019;176:869–81.e13.
pubmed: 30735636 pmcid: 6601354 doi: 10.1016/j.cell.2018.12.021
Kleaveland B, Shi CY, Stefano J, Bartel DP. A network of noncoding regulatory RNAs acts in the mammalian Brain. Cell 2018;174:350–62.e17.
pubmed: 29887379 pmcid: 6559361 doi: 10.1016/j.cell.2018.05.022
Tsang HW, Bhatia I, Chan KW, Chan GCF, Ip P, Cheung PT. Transmembrane 29 (Tmem29), a newly identified molecule showed downregulation in hypoxic-ischemic brain damage. NeuroSci. 2022;3:41–51.
doi: 10.3390/neurosci3010003
Kachakova D, Mitkova A, Popov E, Beltcheva O, Vlahova A, Dikov T, et al. Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients. J BUON. 2013;18:660–8.
pubmed: 24065480
Zhao XG, Hu JY, Tang J, Yi W, Zhang MY, Deng R, et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 2019;10:479.
pubmed: 31209222 pmcid: 6579763 doi: 10.1038/s41419-019-1705-z
Martinez-Anton A, Gras D, Bourdin A, Dubreuil P, Chanez P. KIT as a therapeutic target for non-oncological diseases. Pharmacol Ther. 2019;197:11–37.
pubmed: 30557630 doi: 10.1016/j.pharmthera.2018.12.008
Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92:1619–49.
pubmed: 23073628 doi: 10.1152/physrev.00046.2011
Lu J, Huang Y, Zhang X, Xu Y, Nie S. Noncoding RNAs involved in DNA methylation and histone methylation, and acetylation in diabetic vascular complications. Pharmacol Res. 2021;170:105520.
pubmed: 33639232 doi: 10.1016/j.phrs.2021.105520
Zhang Y, Zhao Y, Liu Y, Wang M, Yu WP, Zhang L. Exploring the regulatory roles of circular RNAs in Alzheimer’s disease. Transl Neurodegener. 2020;9:1–8.
pubmed: 31911834 pmcid: 6943888 doi: 10.1186/s40035-019-0179-3
Yang L, Han B, Zhang Y, Bai Y, Chao J, Hu G, et al. Engagement of circular RNA HECW2 in the nonautophagic role of ATG5 implicated in the endothelial-mesenchymal transition. Autophagy. 2018;14:404–18.
pubmed: 29260931 pmcid: 5915020 doi: 10.1080/15548627.2017.1414755
Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem. 2013;54:29–38.
pubmed: 23829525 doi: 10.1042/bse0540029
Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011;147:358–69.
pubmed: 22000014 pmcid: 3234495 doi: 10.1016/j.cell.2011.09.028
Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147:344–57.
pubmed: 22000013 pmcid: 3235920 doi: 10.1016/j.cell.2011.09.029
Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147:382–95.
pubmed: 22000016 pmcid: 3236086 doi: 10.1016/j.cell.2011.09.032
He Z, Ruan X, Liu X, Zheng J, Liu Y, Liu L, et al. FUS/circ_002136/miR-138-5p/SOX13 feedback loop regulates angiogenesis in Glioma. J Exp Clin Cancer Res. 2019;38:65.
pubmed: 30736838 pmcid: 6368736 doi: 10.1186/s13046-019-1065-7
He Q, Zhao L, Liu X, Zheng J, Liu Y, Liu L, et al. MOV10 binding circ-DICER1 regulates the angiogenesis of glioma via miR-103a-3p/miR-382-5p mediated ZIC4 expression change. J Exp Clin Cancer Res. 2019;38:9.
pubmed: 30621721 pmcid: 6323715 doi: 10.1186/s13046-018-0990-1
Panda AC, De S, Grammatikakis I, Munk R, Yang X, Piao Y, et al. High-purity circular RNA isolation method (RPAD) reveals vast collection of intronic circRNAs. Nucleic Acids Res. 2017;45:e116.
pubmed: 28444238 pmcid: 5499592 doi: 10.1093/nar/gkx297
Meng X, Chen Q, Zhang P, Chen M. CircPro: an integrated tool for the identification of circRNAs with protein-coding potential. Bioinformatics. 2017;33:3314–6.
pubmed: 29028266 doi: 10.1093/bioinformatics/btx446
Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, et al. circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt/beta-catenin pathway. Mol Ther. 2022;30:415–30.
pubmed: 34450253 doi: 10.1016/j.ymthe.2021.08.026
Sun J, Li B, Shu C, Ma Q, Wang J. Functions and clinical significance of circular RNAs in glioma. Mol Cancer. 2020;19:34.
pubmed: 32061256 pmcid: 7023692 doi: 10.1186/s12943-019-1121-0
Jia C, Zhang J, Chen H, Zhuge Y, Chen H, Qian F, et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathespin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis. 2019;10:778.
pubmed: 31611559 pmcid: 6791856 doi: 10.1038/s41419-019-2021-3
Jia C, Zhuge Y, Zhang S, Ni C, Wang L, Wu R, et al. IL-37b alleviates endothelial cell apoptosis and inflammation in Kawasaki disease through IL-1R8 pathway. Cell Death Dis. 2021;12:575.
pubmed: 34083516 pmcid: 8174541 doi: 10.1038/s41419-021-03852-z

Auteurs

Chao Ni (C)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Huixian Qiu (H)

Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Shuchi Zhang (S)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Qihao Zhang (Q)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Ruiyin Zhang (R)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Jinhui Zhou (J)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Jinshun Zhu (J)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Chao Niu (C)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Rongzhou Wu (R)

Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China.

Chuxiao Shao (C)

Department of Hepatopancreatobiliary Surgery, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, 323000, Zhejiang, China.

Abdullah Al Mamun (AA)

Molecular Pharmacology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China.

Bo Han (B)

Department of Pediatric Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China. hanbo35@163.com.
ORCID: 0000-0001-5286-372X

Maoping Chu (M)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China. chmping@hotmail.com.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China. chmping@hotmail.com.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China. chmping@hotmail.com.
ORCID: 0000-0003-0975-7176

Chang Jia (C)

Pediatric Research Institute, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China. jiashang0802@163.com.
Key Laboratory of Structural Malformations in Childern of Zhejiang Province, 325027, Wenzhou, China. jiashang0802@163.com.
Children's Heart Center, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325027, Wenzhou, China. jiashang0802@163.com.
ORCID: 0000-0001-7567-5289

Classifications MeSH